Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2019 Financial Results to be Held After Market on March 12, 2020
CLEVELAND , Feb. 13, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2019 financial results. ViewRay will hold a conference call to discuss results on Thursday, March 12, 2020 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary ViewRay Announces Preliminary Fourth Quarter and Full Year 2019 Results
CLEVELAND , Jan. 13, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2019 . The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2019
Toggle Summary Michigan Community Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
Sparrow Health System Now Delivering On-Table Adaptive Therapy with New MRI-Guided Radiation Therapy System CLEVELAND , Dec. 19, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Sparrow Health System in Lansing, Michigan has begun patient treatments with MRIdian® Linac, a
Toggle Summary First MRIdian MRI-Guided Radiotherapy Treatments Begin in the United Kingdom
GenesisCare Oxford Brings the Benefits of Continuous Soft-Tissue Imaging and Adaptive Treatment Delivery to UK Cancer Patients CLEVELAND , Dec. 17, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the first MRIdian MRI-guided radiotherapy system in the United Kingdom ( UK ) –

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select